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Introduction
Adverse effects and lack of specificity often hamper the
use of conventional immunosuppressives in patients with
systemic sarcoidosis. Adalimumab, a monoclonal antibody
directed against the key cytokine involved in sarcoidosis,
TNF-a, is used in patients with various immunological
disorders [1]. Improved specificity, hence less adverse
effects are the major advantages of this new class of drugs
leading to an exponentially increasing role in their clinical
use. However, few reports involving adalimumab in
patients with sarcoidosis have been published so far and
are restricted to case reports.
Aim
To investigate the effects of adalimumab in systemic
sarcoidosis patients.
Methods
Five patients with active, symptomatic and biopsy-proven
systemic sarcoidosis received adalimumab in this proof of
principle study. Therapeutic efficacy was monitored by
CT-scans, somatostatin receptor-scintigraphy, pulmonary
function tests and various inflammatory parameters.
Results
Therapeutic and symptomatic response was seen in four
out of five (80%) patients in the observational period of
12 weeks. This could be monitored by diminishing lym-
phadenopathy on the scans accompanied by a fall of
inflammatory parameters (sIL-2R and IL-8). Increased
serum levels of sIL-2R, IFN-g and IL-8 decreased in a
fraction of the patients after treatment. Further cytokine
analyses revealed that VEGF-C and DcR3 were initially
elevated in sera of all patients, followed by decreasing
levels after 12 weeks.
Conclusions
Most (80%) patients were considered to benefit from the
adalimumab treatment.
Decrease of sIL-2R and IL-8 correlated with improve-
ment on the scans and clinical symptoms.
Important and novel cytokines are VEGF-C and DcR3.
These might play a major role in the pathogenesis and
provide a basis for possible targets for new cytokine-
directed therapy.
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